Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 9/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16491018 | 0.90 | PLK1 (0.68) | PLK1LMNAMEN1KMT2ATSHR | |
| SCHEMBL17414610 | 0.86 | PLK1 (0.56) | PLK1KAT6A | |
| SCHEMBL31634959 | 0.83 | PLK1 (0.60) | PLK1LMNAMEN1KMT2ATSHR | |
| SCHEMBL22945926 | 0.83 | PLK1 (0.60) | PLK1LMNAMEN1KMT2ATSHR | |
| SCHEMBL17414594 | 0.81 | KAT6A (0.47) | PLK1KAT6ASMN1; SMN2 | |
| SCHEMBL713400 | 0.81 | CA12 (0.63) | PLK1LMNAMEN1KMT2AKAT6A | |
| SCHEMBL12430522 | 0.81 | PLK1 (0.56) | PLK1LMNAMEN1KMT2ATSHR | |
| SCHEMBL7595095 | 0.81 | CA12 (0.54) | MEN1KMT2ATSHRSMN1; SMN2CA12 | |
| SCHEMBL9525522 | 0.81 | CA5A (0.57) | LMNAMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL18856059 | 0.80 | PLK1 (0.43) | PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262803-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | Chungdu Anticancer Bioscience Ltd (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| WO-2022199654-A1 | HETEROARYL-HETEROARYL-O-PHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER DISORDERS | Chengdu Anticancer Bioscience, Ltd. (CN) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262803-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | PLK1 271/4885LMNA 804/4885MEN1 436/4885 |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | PLK1 1354/4885LMNA 1113/4885MEN1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.